Back

Modeling Microbiome Modulation of Tumor Metabolic Networks to Predict Synergistic Therapies

Badenoch, A. J.; Pang, Z.; Chung, C. H.; Robida, A.; Badenoch, B.; Natesan, R.; Kaksih, L.; Li, J.; Chandrasekaran, S.

2026-02-26 bioinformatics
10.64898/2026.02.25.707963 bioRxiv
Show abstract

Differences in microbiome composition profoundly influence drug response, yet methods to model the metabolic interplay between tumors, microbes, and therapeutics remain limited. We present a generalizable framework combining machine-learning and genome-scale metabolic modeling to prioritize combination therapies for colorectal cancer (CRC) in the presence of Fusobacterium nucleatum (Fn) and other pathogenic, probiotic, and commensal microbes. Trained on 6,514 drug combinations in microbe-free CRC cell lines, the model predicted synergistic combinations in both microbe-free and microbe-associated contexts and generalized to immunotherapy-associated conditions. Predictions were validated using an asymmetric co-culture system that mimics the colons normoxic-anaerobic gradient, confirming synergistic combinations in HCT116 cells with Fn, including drugs not typically used in CRC therapy. Mechanistic analysis and targeted pharmacological perturbations revealed phospho-inositol metabolism and cysteine transport as key determinants of Fn-dependent drug synergy. Together, this work introduces a scalable, microbiome-aware framework to enable discovery of context-specific combination therapies.

Published in Cell Reports Methods · training set

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.